PUB - Publikationen an der Universität Bielefeld

Specific immunotherapy with standardized aeroallergens can reduce symptoms and increase the quality of life in some atopic diseases. This therapy is still controversial for atopic dermatitis (AD). Hence, a meta-analysis to assess efficacy and safety of specific immunotherapy with aeroallergens on patients with AD could provide an oversight on advantages and limitations of the therapy. We systematically searched several databases for relevant studies published Randomized controlled trials (RCTs) up to October 2020. Studies involving all ages and gender with AD who treated with specific immunotherapy employing aeroallergens compared with placebo/control. Seven studies RCTs were identified with 832 participants. Significantly decreased of SCORAD values favoring immunotherapy were observed (MD: -5.42; 95% CI -10.31, - 0.52; p=0.03). VAS score was significantly decreased (MD: -1.21; 95% CI -2.10, -0.31; p=0.008). However, immunotherapy showed no significant local and systemic adverse events ((RR 1.77; 95% CI 0.98, 3.19, p=0.06); (RR 0.69; 95% CI 0.16, 3.01, p=0.62)) and IgG4 Dermatophagoides farinae (MD: 92.36, 95% CI -89.14, 273.87; p=0.32). Our meta-analysis reported moderate-level evidence of specific aeroallergen immunotherapy that effective and safe for AD patients.